Episode summary
Oracle Slides by Most Since January on Mounting AI Spending | Bloomberg Intelligence
Bloomberg Intelligence
· · Hosts: Paul Sweeney, Isabelle Lee · Guests: Anurag Rana, Geetha Ranganathan, Madison Muller, Lindsay Dutch
Summary
Oracle’s selloff was tied to a miss on cloud infrastructure growth, rising capex, and investor doubts about how quickly its massive AI backlog can become revenue. The guest said the key issue is not demand but capacity constraints, especially data centers, networking, and power, and argued that Oracle may need a financing structure such as a special purpose vehicle to fund expansion without stretching its balance sheet too far.
The discussion on Warner Bros. Discovery focused on how a possible deal could reshape media ownership, with the host and guest weighing Donald Trump’s call for any buyer to sell CNN. The guest said that would complicate a Netflix bid much more than a Paramount bid, and argued that the market sees the Netflix path as more disruptive because it could pressure theatrical releases, licensing, and legacy studio economics. Paramount, by contrast, was framed as more status quo, though with significant debt and aggressive synergy targets.
The episode also covered Eli Lilly’s next-generation obesity drug, which showed up to 23% weight loss in a trial and reinforced the company’s lead in the category. The guest said pricing is already moving lower, with pills expected to start at $150 a month next year, but safety and side effects remain a major risk. Finally, the consumer hardlines segment was described as resilient in 2025, with stronger higher-income spending, flat promotions, and continued store expansion into 2026.
Key takeaways
- The guest said Oracle’s cloud infrastructure growth came in at 66% versus 69% consensus, and investors are worried its backlog is converting too slowly into revenue.
- Oracle’s capex is rising from $35 billion to $50 billion, and the guest argued the company may need off-balance-sheet financing to support AI data center expansion.
- The guest said a Netflix deal for Warner Bros. Discovery would be more disruptive than Paramount because it could alter theatrical output, licensing, and studio economics.
- Paramount’s case rests on about $16 billion in EBITDA, but the guest said the street may be skeptical of the synergy assumptions behind that target.
- Lilly’s obesity trial showed up to 23% weight loss, and the guest said lower pricing and a pill form could broaden access next year.
- For 2026, the guest expects hardlines retailers to keep benefiting from resilient higher-income consumers, selective promotions, and more brick-and-mortar expansion.
Notable quotes
“the number one thing is cloud infrastructure growth. Consensus was 69% they came at 66”
“everybody is questioning that out of their big backlog which is over 500 billion right now 300 plus billion of that comes from OpenAI”
“the big catalyst for them is they need to go out most likely they need to create a special purpose vehicle”
“obviously Donald Trump has a huge history with with CNN uh has despised the network uh always”
“they're talking about $16 billion in Ebida”
How the episode opens
Bloomberg Audio Studios, podcasts, radio, news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m.
Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts or watch us live on YouTube. Oracle taking it on the chin today.
Um, you know, they put us some big revenue numbers, I thought. But I mean 30% here, 60% here, but not enough for the street. And at the same time, you jack up your capex and uh I think the street gets a little bit nervous about that.
So the stock is trading down pretty big. Let's check in with Honor Ragana. Uh he covers all the technology space, senior tech analyst for Bloomberg Intelligence.
So Anorag, why do you think Oracle selling offs so much today? So there are a few things to keep in mind. You know, the number one thing is cloud infrastructure growth.
Consensus was 69% they came at 66. I know it's a very big number. However, in the cloud world missing by even one percentage point is is not good.
So that's first thing but you know there's a very logical reason about it. Everybody can see the backlog. So it's not as if they don't have a business there.
But converting that backlog into sales is an issue. Everybody knows that there is a capacity constraints out there whether it's data center whether it's networking etc. Power is a very big issue for example.
So that's one area of it. Although the I would say the management did not harp on it as much as we would wanted them to be that to explain why the why why the growth can improve going forward. So that's one factor.
But I think the biggest question is something that we had discussed earlier also is everybody is questioning that out of their big backlog which is over 500 billion right now 300 plus billion of that comes from OpenAI.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- oracle ai spending
- cloud revenue outlook
- warner bros discovery cnn sale
- ai data center capex
- obesity drug weight loss
Companies and tickers mentioned
- ORCL
- LLY
- Oracle
- Warner Bros. Discovery
- Eli Lilly & Co.
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence -
Election 'Blue Wave' & Your Wallet; Navigating AI-Driven Market Volatility | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
